### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In re Application of:

Goulmy et al.

**Serial No.:** To be assigned

Filed: March 2, 2004

For: THE HA-1 ANTIGEN

Examiner (presumed): P. Huynh

Group Art Unit (presumed): 1644

Attorney Docket No.: 2183-4285.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV326919743US

Date of Deposit with USPS: March 2, 2004

Person making Deposit: Christopher Haughton

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Attorney Docket No.: 2183-4285.1US

# Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
#WO 97/05168	02-13-1997	Goulmy
#WO 97/05169	02-13-1997	Goulmy

### Other Documents

#GOULMY et al., The Role of Human Minor Histocompatibility Antigens in Graft Failure: a Mini-review, Eye, 1995, pp. 180-84, Vol. 9, Royal College of Ophthalmologists.

#DEN HAAN et al., Conservation of Minor Histocompatibility Antigens Between Human and Non-human primates, Eur. J. Immunol., 1996, pp. 2680-85, Vol. 26.

#DEN HAAN et al., Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen, Science, June 9, 1995, pp. 1476-80, Vol. 268.

#DEN HAAN et al., The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism, Science, February 13, 1998, pp. 1054-57, Vol. 279,

#VAN DER HARST et al., Recognition of Minor Histocompatibility Antigens on Lymphocytic and Myeloid Leukemic Cells by Cytotoxic T-Cell Clones, 1994, pp. 1060-66, The American Society of Hematology.

#International Search Report, PCT/NL 98/00424, November 30, 1998, 2 pages.

#PCT International Preliminary Examination Report, PCT/NL 98/00424, November 25, 1999, 8 pages.

#COLMAN et al., Effects of amino acid sequence changes on antibody-antigen interaction, 1994, A structural view of immune recognition by antibodies, pp. 33-36.

#ABBAS et al., Cellular and Molecular Immunology, 1991, Antigen Presentation and T cell Recognition, p. 130.

#HAAN et al., Eur J. Immunol., 1996, pp. 2680-85, Vol. 26.

#NAGASE et al., DNA Res. 1996, pp. 321-29, Vol. 3.

#PAUL et al., Fundamental Immunology, 2nd Edition, Raven Press, 1989, pp.; 987-88.

#STRYER et al., Biochemistry, 1998, pp. 31-33, W.H. Freeman and Company, New York.

Attorney Docket No.: 2183-4285.1US

#NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 492-95.

#TISCH et al., Proc. Natl. Acad. Sci., 1994, pp. 437-38, Vol. 91, USA.

#ANDERTON et al., Immunology, 2001, pp. 367-76, Vol. 104.

#PEAKMAN et al., Immunology, 2001, pp. 351-66, Vol. 104.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/489,760 Filed: January 21, 2000

For: THE HA-1 ANTIGEN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2183-4285US

Serial No.: 09/489,760

Filed: January 21, 2000

For: THE HA-1 ANTIGEN

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

And Filler

Andrew F. Nilles

Registration No. 47,825

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: March 2, 2004

AFN/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** To be assigned Filing Date March 2, 2004 STATEMENT BY APPLICANT First Named Inventor Goulmy et al. Group Art Unit (presumed) 1644 (use as many sheets as necessary) **Examiner Name** (presumed) P. Huynh 2183-4285.1US Sheet Attorney Docket Number

	U.S. PATENT DOCUMENTS					
		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials *			MM-DD-YYYY	Cited Document		
		US-				
		US-				
	Ī	US-				
		US-				
		US-	-			
		US-	*			
		US-				
		US-				
		US-				
_		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Examiner Cite Initials* No.1		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Applicant of Cited  Document	Where Relevant Passages or Relevant Figures Appear	T6	
		WO 97/05168	02-13-1997	Goulmy		
		WO 97/05169	02-13-1997	Goulmy		
<del></del>						

Examiner Signature	 Date Considered		
		1	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** To be assigned INFORMATION DISCLOSURE Filing Date March 2, 2004 STATEMENT BY APPLICANT First Named Inventor Goulmy et al. Group Art Unit (presumed) 1644 (use as many sheets as necessary) **Examiner Name** (presumed) P. Huynh Sheet Attorney Docket Number 2183-4285 1US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	!	GOULMY et al., The Role of Human Minor Histocompatibility Antigens in Graft Failure: a Mini-review, Eye, 1995, pp. 180-84, Vol. 9, Royal College of Ophthalmologists.	
		DEN HAAN et al., Conservation of Minor Histocompatibility Antigens Between Human and Non-human primates, Eur. J. Immunol., 1996, pp. 2680-85, Vol. 26.	
		DEN HAAN et al., Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen, Science, June 9, 1995, pp. 1476-80, Vol. 268.	
		DEN HAAN et al., The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism, Science, February 13, 1998, pp. 1054-57, Vol. 279,	
		VAN DER HARST et al., Recognition of Minor Histocompatibility Antigens on Lymphocytic and Myeloid Leukemic Cells by Cytotoxic T-Cell Clones, 1994, pp. 1060-66, The American Society of Hematology.	
		International Search Report, PCT/NL 98/00424, November 30, 1998, 2 pages,	
		PCT International Preliminary Examination Report, PCT/NL 98/00424, November 25, 1999, 8 pages.	
		COLMAN et al., Effects of amino acid sequence changes on antibody-antigen interaction, 1994, A structural view of immune recognition by antibodies, pp. 33-36.	
		ABBAS et al., Cellular and Molecular Immunology, 1991, Antigen Presentation and T cell Recognition, p. 130.	
		HAAN et al., Eur J. Immunol., 1996, pp. 2680-85, Vol. 26.	
		NAGASE et al., DNA Res. 1996, pp. 321-29, Vol. 3.	
		PAUL et al., Fundamental Immunology, 2nd Edition, Raven Press, 1989, pp.; 987-88.	
		STRYER et al., Biochemistry, 1998, pp. 31-33, W.H. Freeman and Company, New York.	
		NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 492-95.	
		TISCH et al., Proc. Natl. Acad. Sci., 1994, pp. 437-38, Vol. 91, USA.	1
		ANDERTON et al., Immunology, 2001, pp. 367-76, Vol. 104.	
		PEAKMAN et al., Immunology, 2001, pp. 351-66, Vol. 104.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/489,760

Filed: January 21, 2000

For: THE HA-1 ANTIGEN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

<sup>1</sup> Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.